Summary of included articles
| Reference . | Country . | Study type . | Study population . | Median age (y) . | Anticoagulation indication . | Anticoagulant . | Follow-up (mo) . | Outcomes, n (%) . |
|---|---|---|---|---|---|---|---|---|
| (21 ) | United States | Retrospective cohort | Adults with SCD and new-onset DVT (n = 109) | 33 | VTE | Warfarin = 32 LMWH = 34 DOAC = 43 (rivaroxaban = 31, apixaban = 7, dabigatran = 5) | 11.8 | Recurrent VTE: Warfarin: 10 (31%) LMWH: 10 (29%) DOACs: 13 (30%) Major bleeding: Warfarin: 9 (28%) LMWH: 5 (15%) DOACs: 2 (5%) |
| (22 ) | United States | Retrospective cohort | Adults with SCD and new-onset VTE (n = 37) | NA | VTE | Warfarin = 15 DOAC = 22 (rivaroxaban = 15, apixaban = 6, dabigatran = 1) | 6 | Recurrent VTE: Warfarin: 3 (20%) DOACs: 6 (27%) Major bleeding: Warfarin: 1 (7%) DOACs: 0 |
| (23 ) | France | Prospective observational | Adults with SCD and new-onset VTE (n = 12) | 27 | PE = 7 DVT = 4 CVT = 1 | Rivaroxaban = 12 | 1-31 | Recurrent VTE: 2 (17) Major bleeding: 0 |
| (24 ) | United States | Retrospective cohort | Adults with SCD and new-onset VTE (n = 60) | NA | VTE | Rivaroxaban = 15 Apixaban = 8 Warfarin = 37 | 8.3 | Recurrent VTE: Warfarin: 7 (19) DOACs: 4 (27) Major bleeding: Warfarin: 2 (5) DOACs: 0 |
| (25 ) | United States | Case series | Adults with SCD and new-onset DVT (n = 7) | 22 | DVT | Rivaroxaban | 2-30 | Recurrent VTE: 1 (14%) Major bleeding: 0 |
| (26 ) | United States | Case series | Adults with SCD and new-onset DVT (n = 3) | 32 | DVT | Rivaroxaban = 2 Warfarin = 1 | 1.5-3 Case 3: NA | Recurrent VTE: 1 Major bleeding: 0 |
| (27 ) | Greece | Case series | Adults with SCD or b-thalassemia major (n = 8) | 56 | DVT = 3 AF = 5 | Rivaroxaban | 6-34 | None |
| Reference . | Country . | Study type . | Study population . | Median age (y) . | Anticoagulation indication . | Anticoagulant . | Follow-up (mo) . | Outcomes, n (%) . |
|---|---|---|---|---|---|---|---|---|
| (21 ) | United States | Retrospective cohort | Adults with SCD and new-onset DVT (n = 109) | 33 | VTE | Warfarin = 32 LMWH = 34 DOAC = 43 (rivaroxaban = 31, apixaban = 7, dabigatran = 5) | 11.8 | Recurrent VTE: Warfarin: 10 (31%) LMWH: 10 (29%) DOACs: 13 (30%) Major bleeding: Warfarin: 9 (28%) LMWH: 5 (15%) DOACs: 2 (5%) |
| (22 ) | United States | Retrospective cohort | Adults with SCD and new-onset VTE (n = 37) | NA | VTE | Warfarin = 15 DOAC = 22 (rivaroxaban = 15, apixaban = 6, dabigatran = 1) | 6 | Recurrent VTE: Warfarin: 3 (20%) DOACs: 6 (27%) Major bleeding: Warfarin: 1 (7%) DOACs: 0 |
| (23 ) | France | Prospective observational | Adults with SCD and new-onset VTE (n = 12) | 27 | PE = 7 DVT = 4 CVT = 1 | Rivaroxaban = 12 | 1-31 | Recurrent VTE: 2 (17) Major bleeding: 0 |
| (24 ) | United States | Retrospective cohort | Adults with SCD and new-onset VTE (n = 60) | NA | VTE | Rivaroxaban = 15 Apixaban = 8 Warfarin = 37 | 8.3 | Recurrent VTE: Warfarin: 7 (19) DOACs: 4 (27) Major bleeding: Warfarin: 2 (5) DOACs: 0 |
| (25 ) | United States | Case series | Adults with SCD and new-onset DVT (n = 7) | 22 | DVT | Rivaroxaban | 2-30 | Recurrent VTE: 1 (14%) Major bleeding: 0 |
| (26 ) | United States | Case series | Adults with SCD and new-onset DVT (n = 3) | 32 | DVT | Rivaroxaban = 2 Warfarin = 1 | 1.5-3 Case 3: NA | Recurrent VTE: 1 Major bleeding: 0 |
| (27 ) | Greece | Case series | Adults with SCD or b-thalassemia major (n = 8) | 56 | DVT = 3 AF = 5 | Rivaroxaban | 6-34 | None |
CVT, cerebral venous thrombosis; AF, atrial fibrillation; NA, not available.